Pre-Made Interferon Alfacon-1 Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research

Pre-Made Interferon Alfacon-1 Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Interferon alfacon-1 is a recombinant synthetic type I interferon used for the treatment of hairy cell leukemia, malignant melanoma and AIDS-related Kaposi’s sarcoma.[1]

Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. Interferon alfacon-1 is a recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections. Interferon alpha binds less stably to type I interferon receptors than interferon beta. The resulting actions include gene transcription, inhibition of cellular growth, alteration of the state of cellular differentiation, interference with oncogene expression, alteration of cell surface antigen expression, increasing phagocytic activity of macrophages, and augmentation of the cytotoxicity of lymphocytes for target cells.